The company said total revenue for Q2 2024 rose to $3,547 million from $3,158 million a year earlier, up 12%, and GAAP net income increased 48% to $1,432 million. GAAP diluted earnings per share were $12.41.

1. 01

   The company said total revenue for Q2 2024 rose to $3,547 million from $3,158 million a year earlier, up 12%, and GAAP net income increased 48% to $1,432 million. GAAP diluted earnings per share were $12.41.

2. 02

   Regeneron said global net sales of Dupixent, as recorded by Sanofi, were $3.56 billion for Q2 2024, up 27% from a year earlier. It said U.S. net sales of EYLEA HD and EYLEA rose 2% to $1.53 billion, of which EYLEA HD accounted for $304 million.

3. 03

   The company said its board of directors in April 2024 authorized a new share repurchase program of up to an additional $3.0 billion of common stock. It recorded the cost of shares repurchased in Q2, $601 million, as Treasury Stock. As of June 30, $3.6 billion remained available for share repurchases under its programs.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.